In addition, the results of the expression analysis of lnc‐CYB561‐5 across TCGA cancers (tumour versus normal samples) was shown in Figure 1H, revealed that lnc‐CYB561‐5 was highly expressed in most malignant tumours, including bladder urothelial carcinoma, breast invasive carcinoma, cholangiocarcinoma and stomach adenocarcinoma. Here, CYB561 is linked to cholangiocarcinoma.